Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Facial Serum Q69 for Mild to Moderate Melasma
NCT05013801Completed
- Sponsor
- Unilever
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Randomised, single-blind trial (2 arms), sponsored by Unilever. Primary endpoints: Change in L* at 20 weeks and Change in modified Melasma Area Severity Index at 20 weeks. Started Sep 2021; status: completed.
Beyond the preview
Go deeper on NCT05013801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013801.